4-(2-bromoethyl)aniline hydrobromide | 29644-22-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(2-bromoethyl)aniline hydrobromide
• 英文别名: 4-(2-bromo-ethyl)-aniline; hydrobromide；4-(2-Brom-aethyl)-anilin; Hydrobromid；p-aminophenylethyl bromide hydrobromide；4-(2-bromoethyl)aniline;hydrobromide
• CAS: 29644-22-2
• 化学式: BrH*C₈H₁₀BrN
• 分子量: 280.99
• InChiKey: DXKGESYYZKPQCE-UHFFFAOYSA-N

物化性质

• 熔点：
  199-200 °C

计算性质

• 辛醇/水分配系数(LogP)：
  2.78
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  26
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  4-(2-bromoethyl)aniline hydrobromide 在 盐酸 、 N-碘代丁二酰亚胺 、 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 37.0h， 生成 ethyl N-[4-(2-bromoethyl)-2-iodophenyl]aminoacetate
  参考文献：
  名称：

  Discovery of Novel N-Phenylglycine Derivatives as Potent and Selective β₃-Adrenoceptor Agonists for the Treatment of Frequent Urination and Urinary Incontinence

  摘要：

  With a novel assay using isolated ferret detrusor to estimate beta (3)-adrenoceptor agonistic activity, we found that a series of glycine derivatives of ritodrine, a beta (2)-adrenoceptor agonist, are potent beta (3)-adrenoceptor agonists, with excellent selectivity versus beta1 and beta (2) subtypes. Substitution of halogens in the phenyl ring increased potency and selectivity for the beta (3)-adrenoceptor, and this was dependent upon the position of the halogens. The chlorine-substituted derivatives 3f-i exhibited potent beta (3)-adrenoceptor-mediated relaxation of ferret detrusor (EC50 = 0.93, 11, 14, and 160 nM) and higher potency at beta (3)-adrenoceptors than at beta (1) or beta (2) The intravenous administration of 3h significantly reduced the urinary bladder pressure in anesthetized male rats (ED50 = 48 mug/kg) without cardiovascular side effects. This article is the first report of structure-activity relationships (SAR) concerning beta (3)-adrenoceptor agonists as agents for the treatment of urinary frequency and incontinence.

  DOI：

  10.1021/jm000455z
• 作为产物：
  描述：

  4-氨基苯乙醇 在 氢溴酸 作用下， 以 水 为溶剂， 反应 4.0h， 生成 4-(2-bromoethyl)aniline hydrobromide
  参考文献：
  名称：

  Phenylaminoalkylcarboxylic acid derivatives and pharmaceutical compositions comprising the same

  摘要：

  本发明提供了一种新型的苯基氨基烷基羧酸衍生物，其通式表示为：（其中R1代表羟基、较低的烷氧基、芳基氧基、氨基、脂环氨基或可能具有羟基或较低烷氧基作为取代基的单个或二个（较低烷基）氨基；R2代表氢原子或较低烷基基团；R3代表氢原子或卤原子；R4和R5相同或不同，每个代表氢原子、卤原子或较低烷基基团；A代表较低烷基烯基团；标记为（R）的碳原子代表（R）构型中的碳原子；标记为（S）的碳原子代表（S）构型中的碳原子），以及其药学上可接受的盐，具有优异的β3-肾上腺素受体激动效果，并且可用作预防或治疗肥胖、高血糖、肠道高运动性引起的疾病、尿频、尿失禁、抑郁症，或胆石或胆道高运动性引起的疾病的药物。

  公开号：

  US06353025B1

文献信息

• Phenylaminoalkylcarboxylic acid derivatives and pharmaceutical compositions comprising the same
  申请人：Kissei Pharmaceutical Co., Ltd.

  公开号：US06353025B1

  公开（公告）日：2002-03-05

  The present invention provides novel phenylaminoalkyl-carboxylic acid derivatives represented by the general formula: (wherein R1 represents a hydroxy group, a lower alkoxy group, an aralkoxy group, an amino group, an alicyclic amino group or a mono or di(lower alkyl)amino group which may have a hydroxy group or a lower alkoxy group as a substituent; R2 represents a hydrogen atom or a lower alkyl group; R3 represents a hydrogen atom or a halogen atom; R4 and R5 are the same or different and each represents a hydrogen atom, a halogen atom or a lower alkyl group; A represents a lower alkylene group; the carbon atom marked with (R) represents a carbon atom in (R) configuration; and the carbon atom marked with (S) represents a carbon atom in (S) configuration) and pharmaceutically acceptable salts thereof, which have excellent &bgr;3-adrenoceptor stimulating effects and are useful as agents for the prevention or treatment of obesity, hyperglycemia, the diseases caused by intestinal hypermotility, pollakiuria, urinary incontinence, depression, or the diseases caused by biliary calculi or hypermotility of biliary tract.

  本发明提供了一种新型的苯基氨基烷基羧酸衍生物，其通式表示为：（其中R1代表羟基、较低的烷氧基、芳基氧基、氨基、脂环氨基或可能具有羟基或较低烷氧基作为取代基的单个或二个（较低烷基）氨基；R2代表氢原子或较低烷基基团；R3代表氢原子或卤原子；R4和R5相同或不同，每个代表氢原子、卤原子或较低烷基基团；A代表较低烷基烯基团；标记为（R）的碳原子代表（R）构型中的碳原子；标记为（S）的碳原子代表（S）构型中的碳原子），以及其药学上可接受的盐，具有优异的β3-肾上腺素受体激动效果，并且可用作预防或治疗肥胖、高血糖、肠道高运动性引起的疾病、尿频、尿失禁、抑郁症，或胆石或胆道高运动性引起的疾病的药物。
• Multidentate AZA ligands able to complex metal ions and the use thereof in diagnostics and therapy
  申请人：Giovenzana Battista Giovanni

  公开号：US20060034773A1

  公开（公告）日：2006-02-16

  Compounds of general formula (I): in which: R 1 through R 5 are as defined in the specification FG, which can be the same or different, are carboxy, —PO 3 H 2 or —RP(O)OH groups, wherein R is hydrogen, or an optionally substituted group selected from C 1 -C 20 alkyl, C 3 -C 10 cycloalkyl, C 4 -C 20 cycloalkylalkyl, aryl, arylalkyl, a group bearing an acidic moiety, and a group bearing an amino moiety, each of which may be further optionally substituted with functional groups which allow conjugation with a suitable molecule able to interact with physiological systems; and their chelates with bi-trivalent ions of the metal elements having atomic number ranging between 20 and 31, 39, 42, 43, 44, 49, and between 57 and 83, and radioisotopes chosen among 203 Pb, 67 Ga, 68 Ga, 72 As, 111 In, 113 In, 90 Y, 97 Ru, 62 Cu, 64 Cu, 52 Fe, 52m Mn, 140 La, 175 Yb, 153 Sm, 166 Ho, 149 Pm, 177 Lu, 142 Pr, 159 Gd, 212 Bi, 47 Sc, 149 Pm, 67 Cu, 111 Ag, 199 Au, 161 Tb, 51 Cr, 167 Tm, 141 Ce, 168 Yb, 88 Y, 165 Dy, 166 Dy, 97 Ru, 103 Ru, 186 Re, 188 Re, 99m Tc, 211 Bi, 212 Bi, 213 Bi, 214 Bi, 105 Rh, 109 Pd, 117m Sn, 177 Sn and 199 Au, as well as the salts thereof with physiologically compatible bases or acids.

  通式（I）的化合物： 其中，R1至R5如规范中所定义，FG可以相同也可以不同，是羧基，—PO3H2或—RP（O）OH基团，其中R是氢，或是选择自C1-C20烷基，C3-C10环烷基，C4-C20环烷基烷基，芳基，芳基烷基，带有酸性基团或带有氨基团的可选取代基团，每个基团也可以进一步选择带有允许与适当分子共轭的功能基团，以与生理系统相互作用的分子。还包括与具有原子序数在20到31、39、42、43、44、49之间以及57到83之间的金属元素的双价离子和放射性同位素203Pb、67Ga、68Ga、72As、111In、113In、90Y、97Ru、62Cu、64Cu、52Fe、52mMn、140La、175Yb、153Sm、166Ho、149Pm、177Lu、142Pr、159Gd、212Bi、47Sc、149Pm、67Cu、111Ag、199Au、161Tb、51Cr、167Tm、141Ce、168Yb、88Y、165Dy、166Dy、97Ru、103Ru、186Re、188Re、99mTc、211Bi、212Bi、213Bi、214Bi、105Rh、109Pd、117mSn、177Sn和199Au的螯合物，以及其与生理兼容的酸或碱盐。
• Multidentate AZA Ligands Able to Complex Metal Ions And The Use Thereof In Diagnostics And Therapy
  申请人：Ramalingam Kondareddiar

  公开号：US20100069628A1

  公开（公告）日：2010-03-18

  Compounds of the formula: Wherein R is selected from the group consisting of H, NH2, and NHBoc; and R′ is selected from the group consisting of H, CH 2 Ph and tBu, optionally de-protected. Such compounds may be conjugated with a suitable molecule able to interact with physiological systems; and their chelates with bi-trivalent ions of the metal elements having atomic number ranging between 20 and 31, 39, 42, 43, 44, 49, and between 57 and 83, and radioisotopes chosen among 203 Pb, 67 Ga, 68 Ga, 72 As, 113 In, 90 Y, 97 Ru, 62 Cu, 64 Cu, 52 Fe, 52m Mn, 140 La, 175 Yb, 153 Sm, 166 Ho, 149 Pm, 177 Lu, 142 Pr, 159 Gd, 212 Bi, 47 Sc, 149 Pm, 67 Cu, 111 Ag, 199 Au, 161 Tb, 51 Cr, 167 Tm, 141 Ce, 168 Yb, 88 Y, 165 Dy, 166 Dy, 97 Ru, 103 Ru, 186 Re, 188 Re, 99m Tc, 211 Bi, 212 Bi, 213 Bi, 214 Bi, 105 Rh, 109 Pd, 117m Sn, 177 Sn and 199 Au, as well as the salts thereof with physiologically compatible bases or acids.

  该化合物的分子式为：其中R选择自H、NH2和NHBoc组成的群体；而R'选择自H、CH2Ph和tBu组成的群体，可以选择去保护。这些化合物可以与能够与生理系统相互作用的合适分子结合；并且它们的螯合物可以与具有原子序数在20到31、39、42、43、44、49之间以及57到83之间的金属元素的双价离子以及选择自203Pb、67Ga、68Ga、72As、113In、90Y、97Ru、62Cu、64Cu、52Fe、52mMn、140La、175Yb、153Sm、166Ho、149Pm、177Lu、142Pr、159Gd、212Bi、47Sc、149Pm、67Cu、111Ag、199Au、161Tb、51Cr、167Tm、141Ce、168Yb、88Y、165Dy、166Dy、97Ru、103Ru、186Re、188Re、99mTc、211Bi、212Bi、213Bi、214Bi、105Rh、109Pd、117mSn、177Sn和199Au的放射性同位素形成配合物，以及它们与生理相容的酸或碱盐。
• Methods Of Coupling Multidentate AZA Ligands To Targeting Molecules
  申请人：GIOVENZANA Giovanni Battista

  公开号：US20110082280A1

  公开（公告）日：2011-04-07

  Methods of coupling targeting molecules to multidentate aza ligands of general formula (I): in which: R 1 through R 5 and FG are as defined in the specification are presented. The aza ligands and/or the resulting conjugates may be labeled with bi-trivalent ions of the metal elements having atomic number ranging between 20 and 31, 39, 42, 43, 44, 49, and between 57 and 83, and radioisotopes chosen among 203 Pb, 67 Ga, 68 Ga, 72 As, 111 In, 113 In, 90 Y, 97 Ru, 62 Cu, 64 Cu, 52 Fe, 52m Mn, 140 La, 175 Yb, 153 Sm, 166 Ho, 149 Pm, 177 Lu, 142 Pr, 159 Gd, 212 Bi, 47 Sc, 149 Pm, 67 Cu, 111 Ag, 199 Au, 161 Tb, 51 Cr, 167 Tm, 141 Ce, 168 Yb, 88 Y, 165 Dy, 166 Dy, 97 Ru, 103 Ru, 186 Re, 188 Re, 99m Tc, 211 Bi, 212 Bi, 213 Bi, 214 Bi, 105 Rh, 109 Pd, 117m Sn, 177 Sn and 199 Au.

  介绍了将靶向分子耦合到一般式（I）中多配位氮杂环配体的方法，其中：R1到R5和FG如说明书中所定义。该氮杂环配体和/或所得到的共轭物可以用原子序数在20到31、39、42、43、44、49之间以及在57到83之间的金属元素的双价或三价离子标记，并且可以选择放射性同位素，包括203Pb、67Ga、68Ga、72As、111In、113In、90Y、97Ru、62Cu、64Cu、52Fe、52mMn、140La、175Yb、153Sm、166Ho、149Pm、177Lu、142Pr、159Gd、212Bi、47Sc、149Pm、67Cu、111Ag、199Au、161Tb、51Cr、167Tm、141Ce、168Yb、88Y、165Dy、166Dy、97Ru、103Ru、186Re、188Re、99mTc、211Bi、212Bi、213Bi、214Bi、105Rh、109Pd、117mSn、177Sn和199Au。
• PHENYLAMINOALKYLCARBOXYLIC ACID DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME
  申请人：Kissei Pharmaceutical Co., Ltd.

  公开号：EP1043308A1

  公开（公告）日：2000-10-11

  The present invention provides novel phenylaminoalkylcarboxylic acid derivatives represented by the general formula: wherein R1 represents a hydroxy group, a lower alkoxy group, an aralkoxy group, an amino group, an alicyclic amino group or a mono or di(lower alkyl)amino group which may have a hydroxy group or a lower alkoxy group as a substituent; R2 represents a hydroxy group or a lower alkyl group; R3 represents a hydrogen atom or a halogen atom; R4 and R5 are the same or different and each represents a hydrogen atom, a halogen atom or a lower alkyl group; A represents a lower alkylene group; the carbon atom marked with (R) represents a carbon atom in (R) configuration; and the carbon atom marked with (S) represents a carbon atom in (S) configuration, and pharmaceutically acceptable salts thereof, which have excellent β3-adrenoceptor stimulating effects and are useful as agents for the prevention or treatment of obesity, hyperglycemia, the diseases caused by intestinal hypermotility, pollakiuria, urinary incontinence, depression, or the diseases caused by biliary calculi or hypermotility of the biliary tract.

  本发明提供由通式表示的新型苯氨基烷基羧酸衍生物： 其中 R1 代表羟基、低级烷氧基、芳烷氧基、氨基、脂环氨基或单或双(低级烷基)氨基，其取代基可以是羟基或低级烷氧基；R2 代表羟基或低级烷基；R3 代表氢原子或卤素原子；R4 和 R5 相同或不同，各自代表氢原子、卤素原子或低级烷基；A 代表低级亚烷基；标有(R)的碳原子代表(R)构型的碳原子；标有(S)的碳原子代表(S)构型的碳原子，以及它们的药学上可接受的盐，它们具有优异的β3-肾上腺素受体刺激作用，可作为预防或治疗肥胖症、高血糖症、肠道过度运动引起的疾病、花粉尿症、尿失禁、抑郁症或胆道结石或胆道过度运动引起的疾病的药物。